Tags

Type your tag names separated by a space and hit enter

A rationale for targeting the P2X7 receptor in Coronavirus disease 19.
Br J Pharmacol. 2020 11; 177(21):4990-4994.BJ

Abstract

Severe pneumonia which shares several of the features of acute respiratory distress syndrome (ARDS) is the main cause of morbidity and mortality in Coronavirus disease 19 (Covid-19) for which there is no effective treatment, so far. ARDS is caused and sustained by an uncontrolled inflammatory activation characterized by a massive release of cytokines (cytokine storm), diffuse lung oedema, inflammatory cell infiltration, and disseminated coagulation. Macrophage and T lymphocyte dysfunction plays a central role in this syndrome. In several experimental in vitro and in vivo models, many of these pathophysiological changes are triggered by stimulation of the P2X7 receptor. We hypothesize that this receptor might be an ideal candidate to target in Covid-19-associated severe pneumonia. LINKED ARTICLES: This article is part of a themed issue on The Pharmacology of COVID-19. To view the other articles in this section visit http://onlinelibrary.wiley.com/doi/10.1111/bph.v177.21/issuetoc.

Authors+Show Affiliations

Department of Medical Sciences, University of Ferrara, Ferrara, Italy.School of Acupuncture and Tuina, Chengdu University of Traditional Chinese Medicine, Chengdu, China.Department of Medical Sciences, University of Ferrara, Ferrara, Italy.Department of Medicine, University of Padova, Padova, Italy.

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

32441783

Citation

Di Virgilio, Francesco, et al. "A Rationale for Targeting the P2X7 Receptor in Coronavirus Disease 19." British Journal of Pharmacology, vol. 177, no. 21, 2020, pp. 4990-4994.
Di Virgilio F, Tang Y, Sarti AC, et al. A rationale for targeting the P2X7 receptor in Coronavirus disease 19. Br J Pharmacol. 2020;177(21):4990-4994.
Di Virgilio, F., Tang, Y., Sarti, A. C., & Rossato, M. (2020). A rationale for targeting the P2X7 receptor in Coronavirus disease 19. British Journal of Pharmacology, 177(21), 4990-4994. https://doi.org/10.1111/bph.15138
Di Virgilio F, et al. A Rationale for Targeting the P2X7 Receptor in Coronavirus Disease 19. Br J Pharmacol. 2020;177(21):4990-4994. PubMed PMID: 32441783.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - A rationale for targeting the P2X7 receptor in Coronavirus disease 19. AU - Di Virgilio,Francesco, AU - Tang,Yong, AU - Sarti,Alba Clara, AU - Rossato,Marco, Y1 - 2020/07/26/ PY - 2020/04/21/received PY - 2020/04/27/revised PY - 2020/05/03/accepted PY - 2020/5/23/pubmed PY - 2020/10/28/medline PY - 2020/5/23/entrez SP - 4990 EP - 4994 JF - British journal of pharmacology JO - Br J Pharmacol VL - 177 IS - 21 N2 - Severe pneumonia which shares several of the features of acute respiratory distress syndrome (ARDS) is the main cause of morbidity and mortality in Coronavirus disease 19 (Covid-19) for which there is no effective treatment, so far. ARDS is caused and sustained by an uncontrolled inflammatory activation characterized by a massive release of cytokines (cytokine storm), diffuse lung oedema, inflammatory cell infiltration, and disseminated coagulation. Macrophage and T lymphocyte dysfunction plays a central role in this syndrome. In several experimental in vitro and in vivo models, many of these pathophysiological changes are triggered by stimulation of the P2X7 receptor. We hypothesize that this receptor might be an ideal candidate to target in Covid-19-associated severe pneumonia. LINKED ARTICLES: This article is part of a themed issue on The Pharmacology of COVID-19. To view the other articles in this section visit http://onlinelibrary.wiley.com/doi/10.1111/bph.v177.21/issuetoc. SN - 1476-5381 UR - https://www.unboundmedicine.com/medline/citation/32441783/A_rationale_for_targeting_the_P2X7_receptor_in_Coronavirus_disease_19_ L2 - https://doi.org/10.1111/bph.15138 DB - PRIME DP - Unbound Medicine ER -